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Abstract
Infections, in particular soft tissue infections (cellulitis,
skin abscesses), are the leading cause for emergency
department visits and hospital admissions of drug injection
users (IDUs). 
Staphylococcus aureus is the most relevant bacterial
pathogen in this population. It is the main cause of soft
tissue infections and of severe infections such as
endocarditis and bacteremia. Moreover, epidemic spread of
methicillin-resistant S. aureus (MRSA) among IDUs has
occurred in Europe and North America. Nasal carriage of S.
aureus is associated with an increased risk of subsequent S.
aureus infections, and it has been shown that active IDUs
have a higher rate of colonization with S. aureus than the
general population. However, it is still unknown why an
individual carries S. aureus. In particular, repeated injections
do not appear to be the main predisposing factor for S.
aureus carriage.
Infections associated with injection drug use are frequently
the consequence of the illegal status of street drugs. Harm
reduction programs, including needle exchange programs,
safer injecting facilities and injection opiate substitution
programs can reduce the incidence of infections among
severely addicted IDUs.
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Introduction
Injection drug use is associated with several complications
(e.g. infectious diseases, drug overdose, violence) that in-
crease morbidity and mortality rates for injection drug
users (IDUs) [1–4]. Previous studies have demonstrated
that infections are a leading cause of morbidity and hospi-
talization among IDUs [3]. In a review of autopsies of 274
hospitalized IDUs in California, United States, infections
were the most common cause of death [5]. Infections in
IDUs are not only a problem for the individual patient, but
may affect the community since bloodborne pathogens (e.g.
HIV, hepatitis) and resistant bacteria, such as methicillin-
resistant Staphylococcus aureus (MRSA), may spread
among IDUs and then to non-IDUs. However, complica-
tions associated with injection drug use (including many in-
fections) are frequently the consequence of the illegal sta-
tus of street drugs (contaminated substances, unavailabil-
ity of sterile injection material, prostitution) rather than of
the drug itself [6]. Therefore, opioid substitution programs
were developed, with the objective of reducing dependence,
morbidity and mortality rates associated with the use of
psychoactive substances. In response to the growing prob-
lem of the failure of oral substitution treatments to handle
addiction in IDUs, injection opiate maintenance programs
were started [6–8]. In this review, infections among IDUs,
with particular consideration of risk factors and prevention
strategies for S. aureus infections, will be discussed.
Infections Leading to Hospitalization of IDUs
The epidemiology of severe medical complications among
IDUs before injection opiate maintenance programs were
available was carefully investigated by Scheidegger and
Zimmerli [2, 3]. They found, in a first retrospective survey
of the years 1980 to 1986, that 269 drug-abusing patients
(97% were IDUs) had 404 admissions to the Department
of Medicine of the University Hospital of Basel, Switzer-
land. 47% of these patients had at least one infectious com-
plication, and infection was the main cause of hospitaliza-
tion (31% of admissions), followed by intoxication with oral
drugs (28%) and heroin overdose (17%). The most fre-
quent infections were lower respiratory tract infections
(24%), viral hepatitis (20%), HIV infection (14%), minor
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genital infection (11%), and thrombophlebitis or soft tissue
infection (6%) [3]. The low prevalence of soft tissue infec-
tions is explained by the fact that patients admitted to other
departments, in particular to the Department of Surgery,
were not included in this survey.
In a second retrospective study, charts of 541 IDUs ad-
mitted to the same department between 1985 and 1993
were reviewed.An infection was again the main reason for
admission among HIV-seropositive IDUs (68% of admis-
sions; incidence density 81.6/1,000 persons-years), and the
second most frequent cause of hospitalization among HIV-
seronegative IDUs (33%; 11.3/1,000 persons-years), after
intoxication (34%) [2].
These data were confirmed by recent studies in other
countries. In a prospective cohort study involving 598
IDUs in Vancouver, Canada, between 1996 and 1999, 440
study participants (74%) visited a hospital emergency de-
partment at least once, and 210 (35%) were admitted to
the hospital at least one time during the study period. The
most common reason for an emergency department visit
was a soft tissue infection (cellulitis and skin abscess) (17%
of visits), and the three most common reasons for hospital
admissions were pneumonia (27% of admissions), soft tis-
sue infection (18%), and sepsis (8%). The authors of this
study concluded that much of the hospital use was related
to complications of injection drug use and may be reduced
with the establishment of programs that integrate harm re-
duction strategies with primary care and addiction treat-
ment [9].
Harm reduction and addiction treatment of severely
opioid-dependent drug users are also two of the main goals
of the injection opiate substitution programs available in
Switzerland, since 1994 [8]. To investigate the impact of
such programs on severe infections among participants, a
retrospective analysis of hospitalizations due to infection
in 175 IDUs for the 3 years before and the period during
their participation in an injection opiate maintenance pro-
gram in Basel, Switzerland was performed (mean duration
during program, 2.6 years) [10]. During both periods of the
study (i.e. before and during the program) skin infections
were the main reason for hospitalization, followed by res-
piratory tract infections.The injection opiate maintenance
treatment did not reduce the incidence or change the spec-
trum of infections leading to hospitalization among the
IDUs studied. However, a majority of these IDUs already
routinely used sterile injection material provided by nee-
dle exchange programs before entering the injection opi-
ate maintenance program. In addition, other beneficial ef-
fects of injection opiate treatment (improvement of health
status, reduction of consumption of street drugs, and a de-
crease in the incidence of HIV) [6–8, 11, 12] are likely to
reduce the risk of infection among IDUs in the long term.
On the other hand, the fact that the incidence of infection-
related hospitalizations during the program did not in-
crease may be interpreted as a stabilization of the health
status of the participants.
S. aureus Infections in IDUs
S. aureus is the most relevant bacterial pathogen in IDUs.
In particular, S. aureus is the most common cause of soft tis-
sue infections (skin abscesses, cellulitis) in this population
[13]. Soft tissue infections are, as discussed above, one of
the main reasons for emergency department visits and hos-
pitalizations of IDUs [9, 10], but they are also extremely
common among IDUs who did not seek medical care. The
skin examination of 1,035 IDUs at admission in the Swiss
iv heroin substitution programs revealed, for example, an
18% prevalence of abscesses and a 29% prevalence of cel-
lulitis [14]. S. aureus is also the main cause of other severe
infections in IDUs. It caused, for example, 61% of endo-
carditis and 57% of bacteremias among IDUs admitted to
one hospital in Detroit, Michigan, United States [15, 16],
ten of 17 endocarditis episodes (59%) in a cohort of 521
IDUs followed for 5 years in Amsterdam,The Netherlands
[17], five of seven cases of sepsis (71%) identified in the
study of hospitalized IDUs in Basel, Switzerland, between
1980 and 1986 [3], and it is the most common pathogen
causing septic deep vein thrombosis in IDUs [18]. Other in-
fections associated with S. aureus in IDUs are septic arthri-
tis, osteomyelitis, and lung abscesses. Furthermore, an as-
sociation between injection drug use and MRSA [19], and
even outbreaks of MRSA infections among IDUs, have
been described in the United States [20] and recently in
Switzerland [21, 22].
Nosocomial S. aureus Infections and IDUs
S. aureus is one of the most important causes of nosocomial
infections. In a prevalence survey on nosocomial infections
conducted in Swiss intensive care units, S. aureus was, over-
all, the second most frequently isolated microorganism
(13%), after Enterobacteriaceae (28%), and the main cause
for bloodstream (17%) and surgical site infection (15%)
[23].
Nosocomial bloodstream infections require special
consideration, since they are frequent (e.g. 12% of all noso-
comial infections reported in a study on more than 10,000
European intensive care patients) [24], and are associated
with significant attributable mortality (4 to 30%) and costs
(USD 4,000 to USD 40,000) [25]. More than 85% of pri-
mary nosocomial bacteremias are intravascular catheter-
related [25] and it has been shown that the mortality rate
attributed to catheter-related S. aureus bacteremia (8.2%)
significantly exceeds the rates for other pathogens [26].
These aspects are particularly relevant to hospitalized
IDUs, because most of them need a vascular access, fre-
quently a central venous catheter, since peripheral line in-
sertion and even blood drawings are often difficult or im-
possible in IDUs. Several IDUs use the central venous
catheter during hospitalization to inject street drugs, which
are often contaminated, thus further increasing the risk of
catheter infection, which is already higher in this popula-
tion because of the higher S. aureus colonization rate, of
preexistent pathologies of the veins (thrombophlebitis,
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etc.), of the difficult line insertion, and of the frequent use
of central venous catheters for drawing of blood samples
from these patients [27]. A recent prospective study ana-
lyzing 1,379 hospital admissions in Italy confirmed that, at
least in HIV-infected patients, active injection drug use is
independently associated with nosocomial bloodstream in-
fections [27]. The most common pathogen associated with
bacteremia in this study was S. aureus (29.8% of all noso-
comial bloodstream infections and 32.3% of all catheter-re-
lated bloodstream infections).
Thus, strategies focusing on the prevention of catheter-
related bloodstream infections (CRBSI) are particularly
important for hospitalized IDUs. Several preventive mea-
sures regarding skin disinfection, sterile insertion, dressing,
handling and replacement of the catheter have been shown
to reduce the incidence of CRBSI and have been recom-
mended [25, 28].As a result of the implementation of these
measures, during the last 10 years the incidence of in-
travascular device-associated bloodstream infections has
decreased in the United States by nearly 40% [29]. Educa-
tional programs also proved to be very effective in reduc-
ing rates of CRBSI [30, 31]. An additional option for the
prevention of CRBSI is the use of anti-infective catheters
[32–34].
Risk Factors for S. aureus Infection in IDUs
Nasal S. aureus colonization
It has previously been shown that active IDUs have a
higher rate of colonization with S. aureus (on the skin and
nasal) than the general population [35]. This may explain
the high incidence of S. aureus infections among IDUs, since
the colonized nose provides a reservoir from which the skin
is seeded [36], and since nasal carriage is associated with an
increased risk of subsequent S. aureus infections [37, 38].
The hypothesis that most S. aureus infections in IDUs orig-
inate from S. aureus colonizing the nose is also supported
by the findings of two studies investigating the source of S.
aureus in infected patients. In the first study, Tuazon and
Sheagran [39] studied ten IDUs with S. aureus endocardi-
tis. All were S. aureus carriers, and in each case, the phage
type of the carried organism matched that of the organism
recovered from the blood. In the second study, genotypi-
cally identical strains of S. aureus were simultaneously iso-
lated from nasal and wound cultures in 43 (81%) of 53 pa-
tients with soft tissue infections who had S. aureus with con-
cordant antimicrobial sensitivity patterns in both nasal and
wound sites [40].
It is, however, still unknown why an individual carries
S. aureus. A number of host characteristics have been pro-
posed as risk factors for S. aureus carriage. Examples in-
clude anatomic abnormalities of the nose, certain leukocyte
antigens, immunological status, viral infections of the upper
respiratory tract, age, ethnicity, hospitalization [37], hor-
monal status in women [41], previous use of antibiotics [41],
use of nasal steroid sprays [42], and the presence of atopic
dermatitis [43].
Based on the observation of higher S. aureus carriage
rates among patients with insulin-dependent diabetes mel-
litus, patients on hemodialysis or continuous ambulatory
peritoneal dialysis and in iv drug addicts, repeated puncture
of the skin by needles has been proposed as a risk factor for
nasal S. aureus carriage [37, 44, 45]. It was thought this as-
sociation was further supported by a report showing an in-
crease in the S. aureus carriage rate in patients starting al-
lergen-injection immunotherapy, suggesting the repeated
injection increased the risk of colonization with S. aureus in
this population [45]. In a newer study of 45 outpatients
(non-IDUs) undergoing desensitization therapy with aller-
gen injection and 84 healthy controls, the nasal S. aureus
carriage rate among patients was also higher than in con-
trols (46.7% vs 26.2%; p = 0.019). However, the only inde-
pendent predictor of nasal S. aureus carriage in this study
was the presence of atopic dermatitis or eczema (OR 4.4;
95% CI 1.2-16.0; p = 0.02). The probability of nasal S. au-
reus carriage was 88.9% for patients receiving allergen in-
jections and having atopic dermatitis or eczema, and 36.1%
for patients receiving allergen injections without atopic der-
matitis or eczema [46]. Thus, factors other than the regular
use of needles, particularly abnormalities related to the
atopic constitution of these patients, may predispose this
population for S. aureus carriage.
The results of two other studies on IDUs support the
hypothesis that regular injections per se are not the main
predisposing factor for S. aureus carriage. In the first study,
94 IDUs treated in an injection opiate maintenance pro-
gram (injecting non-contaminated heroin with sterile
equipment at least twice daily) had a significantly lower
nasal S. aureus carriage rate (22%) and overall colonization
rate (i.e., S. aureus carriage in the nose and/or pharynx
and/or the skin) (39%) than 70 IDUs participating in a con-
ventional oral methadone program (respectively 43% and
60%; p = 0.005 and p = 0.009). In a multivariate model, be-
ing in the oral methadone program was the only significant
risk factor for S. aureus carriage (OR 2.27; 95% CI 1.19-
4.31; p = 0.012). It is important to note that 66% of the pa-
tients in the oral methadone program continued to use iv
street drugs [47]. In the second study of 217 active and for-
mer drug users, no association between iv drug use and
nasal colonization by S. aureus was found, while nasal S. au-
reus carriage was independently correlated with inhala-
tional drug use in HIV-infected persons [48].These findings
suggest that injection of contaminated drugs and inhala-
tional drug use may promote nasal S. aureus colonization,
probably by damaging the nasal mucosa, since damaged
nasal mucosa is more likely to become colonized by S. au-
reus [49].
Contaminated Drugs and Drug-Use Paraphernalia
Organisms causing infections in IDUs may come from con-
taminated needles or saliva, when the needle is licked be-
fore injection, or the injection site is “cleaned” with saliva.
This mechanism of infection has been associated for ex-
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ample with cases of endocarditis or osteomyelitis caused by
Eikenella corrodens [50, 51]. Lemon juice used in heroin
abuse has been implicated as a source of Candida albicans
in outbreaks of systemic candidiasis in IDUs [52]. Epi-
demics of Pseudomonas aeruginosa endocarditis have been
described in IDUs, mainly abusers of pentazocine and tripe-
lenamine, and are presumably associated with the mixing
of drugs in contaminated water [53]. Finally, a recent out-
break of a clonal strain of group A streptococcus among
drug users in Bern, Switzerland, may have been caused by
contaminated cocaine or its containers [54], and an epi-
demic of wound botulism in California, may have resulted
from contamination of black tar heroin most likely when it
was diluted (“cut”), possibly with soil [55]. Inhalation drug-
use paraphernalia were identified as potential vehicles of
transmission of S. aureus in inhalation drug users [56]. How-
ever, contaminated drugs or paraphernalia have probably
only a minor role in the transmission of S. aureus. Tuazon
et al. [57] did not find S. aureus contamination of either
street heroin or injection paraphernalia, and showed that
most samples of street heroin had antibacterial effects
against S. aureus and Bacillus cereus, possibly because of
the quinine content of the drug mixture [58]. Also in a re-
cent study, only one of 58 heroin samples examined in the
United Kingdom yielded S. aureus [59].
Drug Use Environment
It has previously been shown that close personal contact
may facilitate outbreaks of S. aureus skin infections, in par-
ticular if involved individuals frequently present minor skin
wounds. Such epidemics were described, for example,
among members of football and wrestling teams [60,61], or
among river rafting guides who shared communal housing
[62]. Similarly, S. aureus may spread among drug users in
shooting galleries, crack houses or other sites where drugs
are consumed, and where hygiene is usually poor. Indeed,
Craven et al. [63] reported an MRSA outbreak among
IDUs who frequented the same shooting gallery, and fre-
quent and close social contacts was considered to be the
most likely explanation for the epidemic spread of a single
clone of MRSA among IDUs in Zurich, Switzerland [21].
General Risk Factors for Infections in IDUs
In addition to risk factors that specifically increase the risk
of S. aureus infections, other characteristics or habits of
IDUs are associated with bacterial infections in general.
Subcutaneous or intramuscular injection of drugs (“skin-
popping”), injection of a cocaine and heroin mixture
(“speedball”), use of a dirty needle, higher frequency of in-
jection, and drawing blood into the syringe before injection
of drugs (“booting”) (in particular in individuals who do
not engage in skin-popping) have been identified as risk
factors for soft-tissue abscesses [17, 64]. Women are at
greater risk for skin abscesses, presumably because female
IDUs have fewer visible veins than men do and may have
greater difficulty in accessing their veins [17]. Infection with
HIV was associated with soft-tissue abscesses in some, but
not in all studies [17, 64]. Finally, endocarditis in IDUs was
associated with HIV infection, previous history of endo-
carditis [17], and cocaine use [65]. It is unknown whether
the increased risk related to cocaine is caused by systemic
or immunosuppressive effects of cocaine or by injection
habits (more frequent injections).
Prevention of S. aureus Infections in IDUs
The most effective means of preventing infections among
IDUs is, obviously, treatment of drug abuse, with conse-
quent reduction or termination of injection drug use. Im-
proving the quality of treatment services by adding coun-
seling, medical care, and psychosocial services to a
methadone therapy, for example, can significantly reduce
drug use [66]. Further preventive strategies are directed to-
ward risk factors identified for infections in IDUs. Simple
skin cleaning before injection decreases the risk of soft-tis-
sue abscesses and endocarditis [64, 67]. Needle exchange
programs reduce the use of dirty needles and the incidence
of abscesses [68], and may be even more effective if com-
bined with primary health care delivery systems [69], with
a soft tissue infection clinic [70], or with safer injecting fa-
cilities where IDUs can also inject pre-obtained illicit drugs
[71]. Finally, injection opiate substitution programs for se-
verely addicted IDUs improve health status and social func-
tioning, reduce the self-reported use of illicit drugs and
criminal activity [6–8, 11], may decrease the incidence of
HIV and hepatitis A [12], and reduce the prevalence of skin
abscesses and cellulitis [14].
In conclusion, IDUs are at high risk for both commu-
nity-acquired and nosocomial infections. The main bacter-
ial pathogen causing these infections is S. aureus. The high
incidence of S. aureus infections among IDUs can be ex-
plained, at least in part, by the high S. aureus colonization
rate in this population, which predisposes for subsequent
infections with this organism. S. aureus is not only a threat
because of the relevant morbidity and costs associated with
S. aureus infections, but also because of the spread of an-
tibiotic-resistant strains, particularly of MRSA. Continuous
surveillance of the epidemiologic situation is necessary to
rapidly identify the beginning of MRSA outbreaks among
IDUs.
The understanding of the mechanisms leading to S. au-
reus colonization would allow implementation of effica-
cious prevention strategies for IDUs, but also for other pa-
tients at risk for S. aureus colonization and infection (e.g.
insulin-dependent diabetics, hemodialysis patients). How-
ever, these mechanisms are still unknown. In particular, re-
peated injections do not appear to be the main cause of in-
creased S. aureus carriage, and further studies are needed
to investigate this question.
Infections associated with iv drug use are frequently
the consequence of the illegal status of street drugs. Harm
reduction programs including needle exchange programs,
safer injecting facilities and injection opiate substitution
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programs can reduce the incidence of infections among se-
verely addicted IDUs.
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